专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US08613925B2 Anti-IL-13Rα1 antibodies and their uses thereof 有权
标题翻译：抗IL-13Rα1抗体及其用途
公开(公告)号：US08613925B2
公开(公告)日：2013-12-24
申请号：US12445753
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92
摘要： Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed.
摘要翻译：本文公开了通过受体细胞外区域的结构域3结合hIL-13Rα1和IL-13受体介导的信号传导的人白细胞介素-13受体α1的抗体拮抗剂。这些抗体尤其用于治疗或预防IL-13相关疾病和疾病。本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。还公开了使用抗体分子抑制或拮抗hIL-13Rα1介导的活性的方法。

22. 发明授权

US07294646B2 Maxi-k channel blockers, methods of use and process for making the same 失效
标题翻译： Maxi-k通道阻滞剂，使用方法和制备方法
公开(公告)号：US07294646B2
公开(公告)日：2007-11-13
申请号：US10511731
申请日：2003-06-13
申请人： Maria L. Garcia , Michael A. Goetz , Gregory J. Kaczorowski , Owen B. McManus , Richard L. Monaghan , William R. Strohl , Jan S. Tkacz
发明人： Maria L. Garcia , Michael A. Goetz , Gregory J. Kaczorowski , Owen B. McManus , Richard L. Monaghan , William R. Strohl , Jan S. Tkacz
IPC分类号： A61K31/40 , C07D487/00
CPC分类号： C07D491/20 , C12P17/18
摘要： This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
摘要翻译：本发明涉及有效的钾通道阻滞剂或其制剂在治疗青光眼和与患者眼睛中升高的眼内压有关的其它病症中的用途。本发明还涉及这些化合物对哺乳动物物种特别是人的眼睛的神经保护作用的用途。

23. 发明授权

US5962293A Methods of producing doxorubicin 失效
公开(公告)号：US5962293A
公开(公告)日：1999-10-05
申请号：US96982
申请日：1998-06-12
申请人： William R. Strohl , Michael L. Dickens , Charles L. Desanti
发明人： William R. Strohl , Michael L. Dickens , Charles L. Desanti
IPC分类号： C12N9/02 , C12N15/52 , C12N15/76 , C12P19/56
CPC分类号： C12N9/0077 , C12N15/52 , C12N15/76 , C12P19/56
摘要： The present invention provides novel methods for producing doxorubicin using daunomycin as a substrate. One method employs a genetically engineered host microorganism which is transformed with a vector, preferably a plasmid, which contains the doxA gene. Preferably, the doxA gene, also referred to herein as "doxA", is cloned into a plasmid which is then introduced into the host microorganism, preferably a bacterial host, more preferably Streptomyces, to provide a transformed host microorganism. The doxA gene, when present on a plasmid, confers on the transformed host the ability to convert daunomycin and 13-dihydrodaunomycin, to doxorubicin. The doxA gene encodes a P450-like enzyme which catalyzes the hydroxylation of daunomycin and 13-dihydrodaunomycin at C-14 to form doxorubicin; such enzyme is designated "daunomycin C-14 hydroxylase". Thus, the expression of doxA in the transformed host using a plasmid which contains doxA enables the transformed host to convert daunomycin to doxorubicin. The doxorubicin is then extracted from host microorganism cultures.

24. 发明授权

US07700099B2 Non-immunostimulatory antibody and compositions containing the same 有权
标题翻译：非免疫刺激性抗体及其组合物
公开(公告)号：US07700099B2
公开(公告)日：2010-04-20
申请号：US11581931
申请日：2006-10-17
申请人： William R. Strohl
发明人： William R. Strohl
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/92 , G01N33/5058 , G01N2800/2814 , G01N2800/2821 , Y10S435/81
摘要： The present invention relates to a non-immunostimulatory antibody which lacks antibody-dependent cell-mediated cytotoxicity, Fc gamma receptor binding and complement-mediated cytotoxicity. In some embodiments, the antibody contains a modified immunoglobulin G2 (IgG2) Fc region with at least one substitution in the B/C loop, FcRn binding domain, and the F/G loop. The antibody of the invention is useful in the preparation of therapeutic antibodies and pharmaceutical compositions and kits containing the same.
摘要翻译：本发明涉及缺乏抗体依赖性细胞介导的细胞毒性，Fcγ受体结合和补体介导的细胞毒性的非免疫刺激性抗体。在一些实施方案中，抗体含有在B / C环，FcRn结合结构域和F / G环中具有至少一个取代的经修饰的免疫球蛋白G2（IgG2）Fc区。本发明的抗体可用于制备治疗性抗体和药物组合物和含有该抗体的试剂盒。

25. 发明授权

US5976830A Methods of producing doxorubicin 失效
标题翻译：生产多柔比星的方法
公开(公告)号：US5976830A
公开(公告)日：1999-11-02
申请号：US653650
申请日：1996-05-24
申请人： William R. Strohl , Michael L. Dickens , Charles L. Desanti
发明人： William R. Strohl , Michael L. Dickens , Charles L. Desanti
IPC分类号： C12N9/02 , C12N15/52 , C12N15/76 , C12P19/56 , C12P1/00 , C07H21/04
CPC分类号： C12N9/0077 , C12N15/52 , C12N15/76 , C12P19/56
摘要： The present invention provides novel methods for producing doxorubicin using daunomycin as a substrate. One method employs a genetically engineered host microorganism which is transformed with a vector, preferably a plasmid, which contains the doxA gene. Preferably, the doxA gene, also referred to herein as "doxA", is cloned into a plasmid which is then introduced into the host microorganism, preferably a bacterial host, more preferably Streptomyces, to provide a transformed host microorganism. The doxA gene, when present on a plasmid, confers on the transformed host the ability to convert daunomycin and 13-dihydrodaunomycin, to doxorubicin. The doxA gene encodes a P450-like enzyme which catalyzes the hydroxylation of daunomycin and 13-dihydrodaunomycin at C-14 to form doxorubicin; such enzyme is designated "daunomycin C-14 hydroxylase". Thus, the expression of doxA in the transformed host using a plasmid which contains doxA enables the transformed host to convert daunomycin to doxorubicin. The doxorubicin is then extracted from host microorganism cultures.
摘要翻译：本发明提供使用道诺霉素作为底物生产多柔比星的新方法。一种方法采用遗传工程的宿主微生物，其用含有doxA基因的载体，优选质粒转化。优选地，也在本文中称为“doxA”的doxA基因被克隆到质粒中，然后将其导入宿主微生物，优选细菌宿主，更优选链霉菌，以提供转化的宿主微生物。当存在于质粒上时，doxA基因赋予转化的宿主将道诺霉素和13-二氢青霉素转化为多柔比星的能力。 doxA基因编码P450样酶，其催化道诺霉素和13-二氢青霉素在C-14的羟基化形成多柔比星; 这种酶被称为“道诺霉素C-14羟化酶”。因此，使用含有doxA的质粒，转化宿主中doxA的表达使转化的宿主能够将道诺霉素转化为多柔比星。然后从宿主微生物培养物中提取多柔比星。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式